We are live on ! Find out more
FIS

FCPM III Services Portfolio holdings

AUM $750M
1-Year Est. Return 127.27%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+127.27%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$28.2M
Cap. Flow
-$9.15M
Cap. Flow %
-1.22%
Top 10 Hldgs %
99.89%
Holding
11
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
AURA icon
Aura Biosciences
AURA
+$29M

Top Sells

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$23.3M
2
DYN icon
Dyne Therapeutics
DYN
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.09B
$288M 38.34%
8,490,353
-708,547
-8% -$23.3M
MPLT
2
MapLight Therapeutics
MPLT
$609M
$116M 15.41%
3,226,400
– –
DYN icon
3
Dyne Therapeutics
DYN
$4.66B
$85.5M 11.39%
3,848,256
-796,130
-17% -$14.8M
VOR icon
4
Vor Biopharma
VOR
$1.43B
$75.8M 10.1%
4,117,354
– –
DMRA
5
Damora Therapeutics
DMRA
$1.73B
$63.5M 8.46%
2,441,000
– –
REPL icon
6
Replimune Group
REPL
$1.44B
$31.1M 4.14%
2,808,368
– –
CBIO
7
Crescent Biopharma
CBIO
$758M
$30.2M 4.02%
1,677,852
– –
AURA icon
8
Aura Biosciences
AURA
$764M
$28.8M 3.84%
+4,053,775
New +$29M
ENGN icon
9
enGene Therapeutics
ENGN
$123M
$16.7M 2.22%
9,632,561
– –
BCYC
10
Bicycle Therapeutics
BCYC
$297M
$14.7M 1.96%
3,468,430
– –
ENGNW icon
11
enGene Therapeutics Warrants
ENGNW
$2.29M
$834K 0.11%
2,878,148
– –

Similar funds

CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BCM
Bienville Capital Management New York $750M AUM 2.59% 1-Year Est. Return
QI
Qtron Investments Boston, Massachusetts $750M AUM 44.01% 1-Year Est. Return
TWM
TRB Wealth Management Houston, Texas $751M AUM
PFA
Perryman Financial Advisory Dallas, Texas $751M AUM
NFA
Northwest Financial Advisors Herndon, Virginia $752M AUM 16.97% 1-Year Est. Return
VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
SHIM
Stone House Investment Management Tunkhannock, Pennsylvania $752M AUM 20.1% 1-Year Est. Return

FCPM III Services's Q2 2026 Portfolio in Review

As of Q2 2026, FCPM III Services held 11 positions worth $750M, up 3.9% from $722M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

FCPM III Services's Q2 2026 filing shows 1 new and 2 reduced positions. Its largest new stake was Aura Biosciences: 4,053,775 shares worth $28.8M. The largest sale was NewAmsterdam Pharma, an estimated $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • FCPM III Services's largest Q2 2026 buy was Aura Biosciences: 4,053,775 shares worth $28.8M.
  • FCPM III Services's biggest Q2 2026 reduction was NewAmsterdam Pharma, cutting an estimated $23.3M.
  • FCPM III Services's ten largest holdings make up 100% of its $750M portfolio in Q2 2026.
  • FCPM III Services opened 1 new position and closed 0 in Q2 2026.
  • FCPM III Services's portfolio value rose 3.9% quarter-over-quarter to $750M.

Based on FCPM III Services's 13F filing for Q2 2026, filed 14 Aug 2026.